% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kegler:277290,
      author       = {A. Kegler and L. Drewitz and C. Arndt and C. Daglar and L.
                      Rodrigues Loureiro and N. Mitwasi and C. Neuber and K. E.
                      González Soto and T. Bartsch and L. Baraban and H. Ziehr
                      and M. Heine and A. Nieter and A. Moreira-Soto and A. Kühne
                      and J. F. Drexler and B. Seliger and M. Laube and D. Máthé
                      and B. Pályi and P. Hajdrik and L. Forgách and Z. Kis and
                      K. Szigeti and R. Bergmann and A. Feldmann$^*$ and M.
                      Bachmann$^*$},
      title        = {{A} novel {ACE}2 decoy for both neutralization of
                      {SARS}-{C}o{V}-2 variants and killing of infected cells.},
      journal      = {Frontiers in immunology},
      volume       = {14},
      issn         = {1664-3224},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {DKFZ-2023-01319},
      pages        = {1204543},
      year         = {2023},
      abstract     = {The coronavirus disease 2019 (COVID-19) pandemic caused by
                      severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
                      led to millions of infections and deaths worldwide. As this
                      virus evolves rapidly, there is a high need for treatment
                      options that can win the race against new emerging variants
                      of concern. Here, we describe a novel immunotherapeutic drug
                      based on the SARS-CoV-2 entry receptor ACE2 and provide
                      experimental evidence that it cannot only be used for (i)
                      neutralization of SARS-CoV-2 in vitro and in
                      SARS-CoV-2-infected animal models but also for (ii)
                      clearance of virus-infected cells. For the latter purpose,
                      we equipped the ACE2 decoy with an epitope tag. Thereby, we
                      converted it to an adapter molecule, which we successfully
                      applied in the modular platforms UniMAB and UniCAR for
                      retargeting of either unmodified or universal chimeric
                      antigen receptor-modified immune effector cells. Our results
                      pave the way for a clinical application of this novel ACE2
                      decoy, which will clearly improve COVID-19 treatment.},
      keywords     = {ACE2 decoy (Other) / COVID-19 (Other) / SARS–CoV–2
                      (Other) / T-cell based immunotherapy (Other) / adapter CAR
                      platform (Other) / bispecific antibody (Other)},
      cin          = {DD01},
      ddc          = {610},
      cid          = {I:(DE-He78)DD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37383226},
      pmc          = {pmc:PMC10293748},
      doi          = {10.3389/fimmu.2023.1204543},
      url          = {https://inrepo02.dkfz.de/record/277290},
}